Evidence map›Paper›PMID 28000009›Full record

ReviewReviews in endocrine & metabolic disorders2017

Dyslipidemia in patients with chronic kidney disease.

Matthew R Hager, Archana D Narla, Lisa R Tannock

Abstract readReview
PubMed Publisher
In one paragraph

Review in Reviews in endocrine & metabolic disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 6 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 6 syntheses or guidelines pooled it, 192 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Matthew R HagerDepartment of Internal Medicine University of Kentucky, Lexington, KY, USA.
Archana D NarlaDivision of Endocrinology and Molecular Medicine, University of Kentucky, Lexington, KY, USA.
Lisa R TannockDivision of Endocrinology and Molecular Medicine, University of Kentucky, Lexington, KY, USA. Lisa.Tannock@uky.edu.
University of Kentucky · US

Funding

THROMBOSPONDIN1 MEDIATES MACROPHAGE INFILTRATION INTO ADIPOSE TISSUE AND PROMOTEP20RR021954 · NCRR · UNIVERSITY OF KENTUCKY · PI ZHOU, CHANGCHENG · 2008 to 2011
$8.3M
The association of SAA with apoB lipoproteins affects cardiovascular riskI01CX000975 · VA · VA MEDICAL CENTER - LEXINGTON, KY · PI TANNOCK, LISA R · 2014 to 2017
–
CSRD VA I01 CX000975NCRR NIH HHS P20 RR021954
6 · The paper itself

Abstract

Chronic kidney disease (CKD) is associated with high risk for cardiovascular disease (CVD). This association is multifactorial, but CKD is often associated with dyslipidemia, which likely contributes. Patients with CKD have dyslipidemia even at early stages of renal dysfunction and dyslipidemia tends to progress with deterioration of kidney function. The dyslipidemia in CKD is largely due to increased triglyceride levels, decreased HDL-C and varying levels of LDL-C. Current management of CKD may also affect lipid levels. Robust clinical trials demonstrate that statins are safe and efficacious in both lipid lowering and prevention of CVD events in pre-end stage CKD and post-transplant. However, there is no evidence of improved CVD outcomes with statin use in dialysis patients. This review will focus on mechanisms underlying dyslipidemia in CKD and clinical trial evidence for lipid lowering therapy in patients with CKD.

Indexed as

DyslipidemiasHumansHydroxymethylglutaryl-CoA Reductase InhibitorsRenal Insufficiency, ChronicHydroxymethylglutaryl-CoA Reductase InhibitorsCardiovascular diseaseCholesterolChronic kidney diseaseLipidsRenalStatins

Identifiers

PMID28000009
OpenAlexW2566013264

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.